nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—ABCG2—Topotecan—cervical cancer	0.172	0.634	CbGbCtD
Dasatinib—ABCB1—Topotecan—cervical cancer	0.0619	0.229	CbGbCtD
Dasatinib—CYP3A4—Topotecan—cervical cancer	0.0371	0.137	CbGbCtD
Dasatinib—Neutropenic colitis—Topotecan—cervical cancer	0.0214	0.168	CcSEcCtD
Dasatinib—Acute respiratory distress syndrome—Topotecan—cervical cancer	0.00944	0.0743	CcSEcCtD
Dasatinib—EPHB2—Irinotecan—Topotecan—cervical cancer	0.00872	1	CbGdCrCtD
Dasatinib—Myelosuppression—Topotecan—cervical cancer	0.00525	0.0413	CcSEcCtD
Dasatinib—Mucosal inflammation—Topotecan—cervical cancer	0.00445	0.035	CcSEcCtD
Dasatinib—Febrile neutropenia—Topotecan—cervical cancer	0.0041	0.0322	CcSEcCtD
Dasatinib—Interstitial lung disease—Topotecan—cervical cancer	0.00348	0.0274	CcSEcCtD
Dasatinib—Rash erythematous—Topotecan—cervical cancer	0.00322	0.0253	CcSEcCtD
Dasatinib—Pleural effusion—Topotecan—cervical cancer	0.00322	0.0253	CcSEcCtD
Dasatinib—Blood bilirubin increased—Topotecan—cervical cancer	0.00261	0.0205	CcSEcCtD
Dasatinib—Pulmonary embolism—Topotecan—cervical cancer	0.00246	0.0194	CcSEcCtD
Dasatinib—Colitis—Topotecan—cervical cancer	0.00237	0.0186	CcSEcCtD
Dasatinib—Neuropathy—Topotecan—cervical cancer	0.00231	0.0182	CcSEcCtD
Dasatinib—Rash maculo-papular—Topotecan—cervical cancer	0.00224	0.0176	CcSEcCtD
Dasatinib—Neoplasm—Topotecan—cervical cancer	0.00223	0.0175	CcSEcCtD
Dasatinib—Sepsis—Topotecan—cervical cancer	0.00214	0.0168	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00161	0.0127	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00158	0.0124	CcSEcCtD
Dasatinib—Pancytopenia—Topotecan—cervical cancer	0.00147	0.0116	CcSEcCtD
Dasatinib—Neutropenia—Topotecan—cervical cancer	0.00145	0.0114	CcSEcCtD
Dasatinib—Weight increased—Topotecan—cervical cancer	0.00141	0.0111	CcSEcCtD
Dasatinib—Pneumonia—Topotecan—cervical cancer	0.00139	0.0109	CcSEcCtD
Dasatinib—Infestation—Topotecan—cervical cancer	0.00138	0.0108	CcSEcCtD
Dasatinib—Infestation NOS—Topotecan—cervical cancer	0.00138	0.0108	CcSEcCtD
Dasatinib—Neuropathy peripheral—Topotecan—cervical cancer	0.00135	0.0106	CcSEcCtD
Dasatinib—Stomatitis—Topotecan—cervical cancer	0.00134	0.0106	CcSEcCtD
Dasatinib—Hepatobiliary disease—Topotecan—cervical cancer	0.0013	0.0103	CcSEcCtD
Dasatinib—Epistaxis—Topotecan—cervical cancer	0.0013	0.0102	CcSEcCtD
Dasatinib—Haemoglobin—Topotecan—cervical cancer	0.00124	0.00978	CcSEcCtD
Dasatinib—Haemorrhage—Topotecan—cervical cancer	0.00124	0.00973	CcSEcCtD
Dasatinib—Angiopathy—Topotecan—cervical cancer	0.00112	0.00883	CcSEcCtD
Dasatinib—Immune system disorder—Topotecan—cervical cancer	0.00112	0.00879	CcSEcCtD
Dasatinib—Mediastinal disorder—Topotecan—cervical cancer	0.00112	0.00877	CcSEcCtD
Dasatinib—Chills—Topotecan—cervical cancer	0.00111	0.00873	CcSEcCtD
Dasatinib—Alopecia—Topotecan—cervical cancer	0.00109	0.0086	CcSEcCtD
Dasatinib—Malnutrition—Topotecan—cervical cancer	0.00108	0.00847	CcSEcCtD
Dasatinib—Muscle spasms—Topotecan—cervical cancer	0.00104	0.00815	CcSEcCtD
Dasatinib—Ill-defined disorder—Topotecan—cervical cancer	0.000999	0.00786	CcSEcCtD
Dasatinib—Anaemia—Topotecan—cervical cancer	0.000996	0.00783	CcSEcCtD
Dasatinib—Malaise—Topotecan—cervical cancer	0.000971	0.00764	CcSEcCtD
Dasatinib—Cough—Topotecan—cervical cancer	0.00094	0.00739	CcSEcCtD
Dasatinib—Arthralgia—Topotecan—cervical cancer	0.000917	0.00721	CcSEcCtD
Dasatinib—Chest pain—Topotecan—cervical cancer	0.000917	0.00721	CcSEcCtD
Dasatinib—Myalgia—Topotecan—cervical cancer	0.000917	0.00721	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000911	0.00717	CcSEcCtD
Dasatinib—Discomfort—Topotecan—cervical cancer	0.000906	0.00713	CcSEcCtD
Dasatinib—MAPK14—renal system—cervical cancer	0.000882	0.0031	CbGeAlD
Dasatinib—EPHA2—uterine cervix—cervical cancer	0.000877	0.00309	CbGeAlD
Dasatinib—FYN—uterine cervix—cervical cancer	0.000876	0.00308	CbGeAlD
Dasatinib—Infection—Topotecan—cervical cancer	0.000873	0.00687	CcSEcCtD
Dasatinib—Nervous system disorder—Topotecan—cervical cancer	0.000862	0.00678	CcSEcCtD
Dasatinib—SIK1—uterus—cervical cancer	0.000861	0.00303	CbGeAlD
Dasatinib—Thrombocytopenia—Topotecan—cervical cancer	0.000861	0.00677	CcSEcCtD
Dasatinib—STK35—female reproductive system—cervical cancer	0.00086	0.00303	CbGeAlD
Dasatinib—MAP4K5—uterine cervix—cervical cancer	0.000856	0.00301	CbGeAlD
Dasatinib—MAP3K3—uterine cervix—cervical cancer	0.000856	0.00301	CbGeAlD
Dasatinib—CSK—female reproductive system—cervical cancer	0.000854	0.00301	CbGeAlD
Dasatinib—Skin disorder—Topotecan—cervical cancer	0.000854	0.00672	CcSEcCtD
Dasatinib—EPHA4—uterus—cervical cancer	0.000852	0.003	CbGeAlD
Dasatinib—EPHB4—decidua—cervical cancer	0.000852	0.003	CbGeAlD
Dasatinib—Hyperhidrosis—Topotecan—cervical cancer	0.00085	0.00669	CcSEcCtD
Dasatinib—FGR—endometrium—cervical cancer	0.00085	0.00299	CbGeAlD
Dasatinib—TESK1—female gonad—cervical cancer	0.000848	0.00299	CbGeAlD
Dasatinib—JAK2—decidua—cervical cancer	0.000846	0.00298	CbGeAlD
Dasatinib—ERBB3—uterus—cervical cancer	0.000844	0.00297	CbGeAlD
Dasatinib—TESK1—vagina—cervical cancer	0.000843	0.00297	CbGeAlD
Dasatinib—Anorexia—Topotecan—cervical cancer	0.000838	0.00659	CcSEcCtD
Dasatinib—EPHB4—renal system—cervical cancer	0.000836	0.00294	CbGeAlD
Dasatinib—MAP3K2—uterus—cervical cancer	0.000836	0.00294	CbGeAlD
Dasatinib—EPHA2—decidua—cervical cancer	0.000836	0.00294	CbGeAlD
Dasatinib—STK36—female gonad—cervical cancer	0.000835	0.00294	CbGeAlD
Dasatinib—EPHB3—female gonad—cervical cancer	0.000835	0.00294	CbGeAlD
Dasatinib—FYN—decidua—cervical cancer	0.000834	0.00294	CbGeAlD
Dasatinib—BMX—lymph node—cervical cancer	0.000833	0.00293	CbGeAlD
Dasatinib—JAK2—renal system—cervical cancer	0.000831	0.00292	CbGeAlD
Dasatinib—STK36—vagina—cervical cancer	0.00083	0.00292	CbGeAlD
Dasatinib—EPHB3—vagina—cervical cancer	0.00083	0.00292	CbGeAlD
Dasatinib—BLK—lymph node—cervical cancer	0.000823	0.0029	CbGeAlD
Dasatinib—FGR—mammalian vulva—cervical cancer	0.000822	0.00289	CbGeAlD
Dasatinib—LCK—mammalian vulva—cervical cancer	0.000822	0.00289	CbGeAlD
Dasatinib—FYN—renal system—cervical cancer	0.000819	0.00288	CbGeAlD
Dasatinib—EPHB6—uterine cervix—cervical cancer	0.000818	0.00288	CbGeAlD
Dasatinib—MAP4K5—decidua—cervical cancer	0.000815	0.00287	CbGeAlD
Dasatinib—MAP3K3—decidua—cervical cancer	0.000815	0.00287	CbGeAlD
Dasatinib—EPHB4—endometrium—cervical cancer	0.000809	0.00285	CbGeAlD
Dasatinib—LIMK2—female gonad—cervical cancer	0.000807	0.00284	CbGeAlD
Dasatinib—JAK2—endometrium—cervical cancer	0.000803	0.00283	CbGeAlD
Dasatinib—LIMK2—vagina—cervical cancer	0.000802	0.00282	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000801	0.0063	CcSEcCtD
Dasatinib—FMO3—mammalian vulva—cervical cancer	0.000794	0.00279	CbGeAlD
Dasatinib—EPHA2—endometrium—cervical cancer	0.000793	0.00279	CbGeAlD
Dasatinib—RIPK2—female reproductive system—cervical cancer	0.000793	0.00279	CbGeAlD
Dasatinib—FYN—endometrium—cervical cancer	0.000792	0.00279	CbGeAlD
Dasatinib—YES1—uterine cervix—cervical cancer	0.00079	0.00278	CbGeAlD
Dasatinib—TXK—lymph node—cervical cancer	0.000788	0.00277	CbGeAlD
Dasatinib—MAPK14—uterus—cervical cancer	0.000786	0.00277	CbGeAlD
Dasatinib—Dyspnoea—Topotecan—cervical cancer	0.000784	0.00617	CcSEcCtD
Dasatinib—LCK—uterus—cervical cancer	0.000783	0.00275	CbGeAlD
Dasatinib—STK35—female gonad—cervical cancer	0.000782	0.00275	CbGeAlD
Dasatinib—EPHB4—mammalian vulva—cervical cancer	0.000782	0.00275	CbGeAlD
Dasatinib—EPHB6—decidua—cervical cancer	0.000779	0.00274	CbGeAlD
Dasatinib—STK35—vagina—cervical cancer	0.000778	0.00274	CbGeAlD
Dasatinib—CSK—female gonad—cervical cancer	0.000777	0.00273	CbGeAlD
Dasatinib—JAK2—mammalian vulva—cervical cancer	0.000777	0.00273	CbGeAlD
Dasatinib—SIK1—female reproductive system—cervical cancer	0.000774	0.00272	CbGeAlD
Dasatinib—MAP4K5—endometrium—cervical cancer	0.000774	0.00272	CbGeAlD
Dasatinib—MAP3K3—endometrium—cervical cancer	0.000774	0.00272	CbGeAlD
Dasatinib—Dyspepsia—Topotecan—cervical cancer	0.000774	0.00609	CcSEcCtD
Dasatinib—CSK—vagina—cervical cancer	0.000773	0.00272	CbGeAlD
Dasatinib—EPHA2—mammalian vulva—cervical cancer	0.000767	0.0027	CbGeAlD
Dasatinib—HCK—female gonad—cervical cancer	0.000767	0.0027	CbGeAlD
Dasatinib—SRC—epithelium—cervical cancer	0.000767	0.0027	CbGeAlD
Dasatinib—EPHA4—female reproductive system—cervical cancer	0.000766	0.0027	CbGeAlD
Dasatinib—FYN—mammalian vulva—cervical cancer	0.000766	0.0027	CbGeAlD
Dasatinib—Decreased appetite—Topotecan—cervical cancer	0.000764	0.00601	CcSEcCtD
Dasatinib—HCK—vagina—cervical cancer	0.000763	0.00268	CbGeAlD
Dasatinib—ABL2—female gonad—cervical cancer	0.000762	0.00268	CbGeAlD
Dasatinib—SRC—uterine cervix—cervical cancer	0.00076	0.00267	CbGeAlD
Dasatinib—Gastrointestinal disorder—Topotecan—cervical cancer	0.000759	0.00597	CcSEcCtD
Dasatinib—ERBB3—female reproductive system—cervical cancer	0.000759	0.00267	CbGeAlD
Dasatinib—Fatigue—Topotecan—cervical cancer	0.000758	0.00596	CcSEcCtD
Dasatinib—ABL2—vagina—cervical cancer	0.000758	0.00267	CbGeAlD
Dasatinib—YES1—decidua—cervical cancer	0.000753	0.00265	CbGeAlD
Dasatinib—Constipation—Topotecan—cervical cancer	0.000752	0.00591	CcSEcCtD
Dasatinib—Pain—Topotecan—cervical cancer	0.000752	0.00591	CcSEcCtD
Dasatinib—MAP3K2—female reproductive system—cervical cancer	0.000752	0.00264	CbGeAlD
Dasatinib—MAP3K3—mammalian vulva—cervical cancer	0.000749	0.00263	CbGeAlD
Dasatinib—MAP4K5—mammalian vulva—cervical cancer	0.000749	0.00263	CbGeAlD
Dasatinib—EPHB4—uterus—cervical cancer	0.000745	0.00262	CbGeAlD
Dasatinib—EPHB6—endometrium—cervical cancer	0.00074	0.0026	CbGeAlD
Dasatinib—YES1—renal system—cervical cancer	0.000739	0.0026	CbGeAlD
Dasatinib—PDGFRA—decidua—cervical cancer	0.000739	0.0026	CbGeAlD
Dasatinib—STAT5B—lymph node—cervical cancer	0.000738	0.0026	CbGeAlD
Dasatinib—FYN—uterus—cervical cancer	0.00073	0.00257	CbGeAlD
Dasatinib—PDGFRA—renal system—cervical cancer	0.000725	0.00255	CbGeAlD
Dasatinib—Feeling abnormal—Topotecan—cervical cancer	0.000724	0.0057	CcSEcCtD
Dasatinib—SRC—decidua—cervical cancer	0.000724	0.00255	CbGeAlD
Dasatinib—RIPK2—female gonad—cervical cancer	0.000721	0.00254	CbGeAlD
Dasatinib—Gastrointestinal pain—Topotecan—cervical cancer	0.000719	0.00566	CcSEcCtD
Dasatinib—RIPK2—vagina—cervical cancer	0.000717	0.00252	CbGeAlD
Dasatinib—EPHB6—mammalian vulva—cervical cancer	0.000715	0.00252	CbGeAlD
Dasatinib—YES1—endometrium—cervical cancer	0.000715	0.00251	CbGeAlD
Dasatinib—MAP4K5—uterus—cervical cancer	0.000713	0.00251	CbGeAlD
Dasatinib—SRC—renal system—cervical cancer	0.000711	0.0025	CbGeAlD
Dasatinib—MAPK14—female reproductive system—cervical cancer	0.000707	0.00249	CbGeAlD
Dasatinib—SIK1—female gonad—cervical cancer	0.000704	0.00248	CbGeAlD
Dasatinib—FGR—female reproductive system—cervical cancer	0.000704	0.00248	CbGeAlD
Dasatinib—MAP2K5—uterine cervix—cervical cancer	0.000699	0.00246	CbGeAlD
Dasatinib—Urticaria—Topotecan—cervical cancer	0.000698	0.00549	CcSEcCtD
Dasatinib—EPHA4—female gonad—cervical cancer	0.000697	0.00245	CbGeAlD
Dasatinib—Abdominal pain—Topotecan—cervical cancer	0.000695	0.00547	CcSEcCtD
Dasatinib—Body temperature increased—Topotecan—cervical cancer	0.000695	0.00547	CcSEcCtD
Dasatinib—EPHA4—vagina—cervical cancer	0.000693	0.00244	CbGeAlD
Dasatinib—YES1—mammalian vulva—cervical cancer	0.000691	0.00243	CbGeAlD
Dasatinib—ERBB3—female gonad—cervical cancer	0.00069	0.00243	CbGeAlD
Dasatinib—MAP3K2—female gonad—cervical cancer	0.000684	0.00241	CbGeAlD
Dasatinib—CSF1R—uterine cervix—cervical cancer	0.000682	0.0024	CbGeAlD
Dasatinib—EPHA3—lymph node—cervical cancer	0.000682	0.0024	CbGeAlD
Dasatinib—EPHB4—female reproductive system—cervical cancer	0.00067	0.00236	CbGeAlD
Dasatinib—MAP2K5—decidua—cervical cancer	0.000666	0.00234	CbGeAlD
Dasatinib—JAK2—female reproductive system—cervical cancer	0.000665	0.00234	CbGeAlD
Dasatinib—SIK3—lymph node—cervical cancer	0.000664	0.00234	CbGeAlD
Dasatinib—YES1—uterus—cervical cancer	0.000659	0.00232	CbGeAlD
Dasatinib—EPHA2—female reproductive system—cervical cancer	0.000657	0.00231	CbGeAlD
Dasatinib—FYN—female reproductive system—cervical cancer	0.000656	0.00231	CbGeAlD
Dasatinib—CSF1R—decidua—cervical cancer	0.00065	0.00229	CbGeAlD
Dasatinib—Hypersensitivity—Topotecan—cervical cancer	0.000648	0.0051	CcSEcCtD
Dasatinib—PDGFRA—uterus—cervical cancer	0.000646	0.00227	CbGeAlD
Dasatinib—MAPK14—female gonad—cervical cancer	0.000643	0.00226	CbGeAlD
Dasatinib—MAP4K5—female reproductive system—cervical cancer	0.000641	0.00226	CbGeAlD
Dasatinib—MAP3K3—female reproductive system—cervical cancer	0.000641	0.00226	CbGeAlD
Dasatinib—LCK—female gonad—cervical cancer	0.00064	0.00225	CbGeAlD
Dasatinib—FGR—female gonad—cervical cancer	0.00064	0.00225	CbGeAlD
Dasatinib—MAPK14—vagina—cervical cancer	0.000639	0.00225	CbGeAlD
Dasatinib—FGR—vagina—cervical cancer	0.000636	0.00224	CbGeAlD
Dasatinib—LCK—vagina—cervical cancer	0.000636	0.00224	CbGeAlD
Dasatinib—MAP2K5—endometrium—cervical cancer	0.000632	0.00223	CbGeAlD
Dasatinib—Asthenia—Topotecan—cervical cancer	0.000631	0.00496	CcSEcCtD
Dasatinib—KIT—epithelium—cervical cancer	0.000625	0.0022	CbGeAlD
Dasatinib—Pruritus—Topotecan—cervical cancer	0.000622	0.00489	CcSEcCtD
Dasatinib—KIT—uterine cervix—cervical cancer	0.00062	0.00218	CbGeAlD
Dasatinib—CSF1R—endometrium—cervical cancer	0.000617	0.00217	CbGeAlD
Dasatinib—ZAK—lymph node—cervical cancer	0.000617	0.00217	CbGeAlD
Dasatinib—FMO3—vagina—cervical cancer	0.000615	0.00216	CbGeAlD
Dasatinib—MAP2K5—mammalian vulva—cervical cancer	0.000612	0.00215	CbGeAlD
Dasatinib—PDGFRB—epithelium—cervical cancer	0.00061	0.00215	CbGeAlD
Dasatinib—EPHB4—female gonad—cervical cancer	0.00061	0.00214	CbGeAlD
Dasatinib—EPHB4—vagina—cervical cancer	0.000606	0.00213	CbGeAlD
Dasatinib—PDGFRB—uterine cervix—cervical cancer	0.000605	0.00213	CbGeAlD
Dasatinib—JAK2—female gonad—cervical cancer	0.000605	0.00213	CbGeAlD
Dasatinib—JAK2—vagina—cervical cancer	0.000602	0.00212	CbGeAlD
Dasatinib—Diarrhoea—Topotecan—cervical cancer	0.000602	0.00473	CcSEcCtD
Dasatinib—EPHA2—female gonad—cervical cancer	0.000598	0.0021	CbGeAlD
Dasatinib—CSF1R—mammalian vulva—cervical cancer	0.000597	0.0021	CbGeAlD
Dasatinib—FYN—female gonad—cervical cancer	0.000597	0.0021	CbGeAlD
Dasatinib—EPHA2—vagina—cervical cancer	0.000594	0.00209	CbGeAlD
Dasatinib—FYN—vagina—cervical cancer	0.000593	0.00209	CbGeAlD
Dasatinib—YES1—female reproductive system—cervical cancer	0.000592	0.00208	CbGeAlD
Dasatinib—BMPR1B—lymph node—cervical cancer	0.000592	0.00208	CbGeAlD
Dasatinib—KIT—decidua—cervical cancer	0.00059	0.00208	CbGeAlD
Dasatinib—BTK—lymph node—cervical cancer	0.000589	0.00207	CbGeAlD
Dasatinib—MAP3K3—female gonad—cervical cancer	0.000583	0.00205	CbGeAlD
Dasatinib—MAP4K5—female gonad—cervical cancer	0.000583	0.00205	CbGeAlD
Dasatinib—Dizziness—Topotecan—cervical cancer	0.000581	0.00457	CcSEcCtD
Dasatinib—PDGFRA—female reproductive system—cervical cancer	0.000581	0.00204	CbGeAlD
Dasatinib—TNK2—lymph node—cervical cancer	0.00058	0.00204	CbGeAlD
Dasatinib—MAP4K5—vagina—cervical cancer	0.00058	0.00204	CbGeAlD
Dasatinib—MAP3K3—vagina—cervical cancer	0.00058	0.00204	CbGeAlD
Dasatinib—KIT—renal system—cervical cancer	0.00058	0.00204	CbGeAlD
Dasatinib—PDGFRB—decidua—cervical cancer	0.000577	0.00203	CbGeAlD
Dasatinib—SRC—female reproductive system—cervical cancer	0.00057	0.002	CbGeAlD
Dasatinib—CSF1R—uterus—cervical cancer	0.000569	0.002	CbGeAlD
Dasatinib—PDGFRB—renal system—cervical cancer	0.000566	0.00199	CbGeAlD
Dasatinib—KIT—endometrium—cervical cancer	0.00056	0.00197	CbGeAlD
Dasatinib—Vomiting—Topotecan—cervical cancer	0.000559	0.0044	CcSEcCtD
Dasatinib—EPHB6—female gonad—cervical cancer	0.000557	0.00196	CbGeAlD
Dasatinib—Rash—Topotecan—cervical cancer	0.000554	0.00436	CcSEcCtD
Dasatinib—EPHB6—vagina—cervical cancer	0.000554	0.00195	CbGeAlD
Dasatinib—Dermatitis—Topotecan—cervical cancer	0.000554	0.00436	CcSEcCtD
Dasatinib—Headache—Topotecan—cervical cancer	0.000551	0.00433	CcSEcCtD
Dasatinib—PDGFRB—endometrium—cervical cancer	0.000547	0.00193	CbGeAlD
Dasatinib—TESK1—lymph node—cervical cancer	0.000545	0.00192	CbGeAlD
Dasatinib—KIT—mammalian vulva—cervical cancer	0.000542	0.00191	CbGeAlD
Dasatinib—ABL1—uterine cervix—cervical cancer	0.000539	0.0019	CbGeAlD
Dasatinib—YES1—female gonad—cervical cancer	0.000539	0.0019	CbGeAlD
Dasatinib—STK36—lymph node—cervical cancer	0.000537	0.00189	CbGeAlD
Dasatinib—EPHB3—lymph node—cervical cancer	0.000537	0.00189	CbGeAlD
Dasatinib—YES1—vagina—cervical cancer	0.000535	0.00188	CbGeAlD
Dasatinib—PDGFRB—mammalian vulva—cervical cancer	0.00053	0.00186	CbGeAlD
Dasatinib—PDGFRA—female gonad—cervical cancer	0.000528	0.00186	CbGeAlD
Dasatinib—PDGFRA—vagina—cervical cancer	0.000525	0.00185	CbGeAlD
Dasatinib—MAP2K5—female reproductive system—cervical cancer	0.000524	0.00184	CbGeAlD
Dasatinib—Nausea—Topotecan—cervical cancer	0.000522	0.00411	CcSEcCtD
Dasatinib—LIMK2—lymph node—cervical cancer	0.000519	0.00183	CbGeAlD
Dasatinib—SRC—female gonad—cervical cancer	0.000518	0.00182	CbGeAlD
Dasatinib—KIT—uterus—cervical cancer	0.000516	0.00182	CbGeAlD
Dasatinib—ABL1—decidua—cervical cancer	0.000514	0.00181	CbGeAlD
Dasatinib—CSF1R—female reproductive system—cervical cancer	0.000511	0.0018	CbGeAlD
Dasatinib—ABL1—renal system—cervical cancer	0.000505	0.00178	CbGeAlD
Dasatinib—PDGFRB—uterus—cervical cancer	0.000504	0.00177	CbGeAlD
Dasatinib—STK35—lymph node—cervical cancer	0.000503	0.00177	CbGeAlD
Dasatinib—CSK—lymph node—cervical cancer	0.0005	0.00176	CbGeAlD
Dasatinib—HCK—lymph node—cervical cancer	0.000493	0.00174	CbGeAlD
Dasatinib—ABL2—lymph node—cervical cancer	0.00049	0.00172	CbGeAlD
Dasatinib—ABL1—endometrium—cervical cancer	0.000488	0.00172	CbGeAlD
Dasatinib—MAP2K5—female gonad—cervical cancer	0.000477	0.00168	CbGeAlD
Dasatinib—MAP2K5—vagina—cervical cancer	0.000474	0.00167	CbGeAlD
Dasatinib—ABL1—mammalian vulva—cervical cancer	0.000472	0.00166	CbGeAlD
Dasatinib—CSF1R—female gonad—cervical cancer	0.000465	0.00164	CbGeAlD
Dasatinib—KIT—female reproductive system—cervical cancer	0.000464	0.00163	CbGeAlD
Dasatinib—RIPK2—lymph node—cervical cancer	0.000464	0.00163	CbGeAlD
Dasatinib—CSF1R—vagina—cervical cancer	0.000462	0.00163	CbGeAlD
Dasatinib—PDGFRB—female reproductive system—cervical cancer	0.000453	0.0016	CbGeAlD
Dasatinib—SIK1—lymph node—cervical cancer	0.000453	0.00159	CbGeAlD
Dasatinib—ABL1—uterus—cervical cancer	0.00045	0.00158	CbGeAlD
Dasatinib—EPHA4—lymph node—cervical cancer	0.000448	0.00158	CbGeAlD
Dasatinib—ERBB3—lymph node—cervical cancer	0.000444	0.00156	CbGeAlD
Dasatinib—MAP3K2—lymph node—cervical cancer	0.00044	0.00155	CbGeAlD
Dasatinib—CYP1B1—decidua—cervical cancer	0.000435	0.00153	CbGeAlD
Dasatinib—CYP1B1—renal system—cervical cancer	0.000427	0.0015	CbGeAlD
Dasatinib—KIT—female gonad—cervical cancer	0.000422	0.00149	CbGeAlD
Dasatinib—KIT—vagina—cervical cancer	0.00042	0.00148	CbGeAlD
Dasatinib—MAPK14—lymph node—cervical cancer	0.000413	0.00145	CbGeAlD
Dasatinib—PDGFRB—female gonad—cervical cancer	0.000413	0.00145	CbGeAlD
Dasatinib—FGR—lymph node—cervical cancer	0.000412	0.00145	CbGeAlD
Dasatinib—LCK—lymph node—cervical cancer	0.000412	0.00145	CbGeAlD
Dasatinib—PDGFRB—vagina—cervical cancer	0.00041	0.00144	CbGeAlD
Dasatinib—ABL1—female reproductive system—cervical cancer	0.000404	0.00142	CbGeAlD
Dasatinib—FMO3—lymph node—cervical cancer	0.000398	0.0014	CbGeAlD
Dasatinib—EPHB4—lymph node—cervical cancer	0.000392	0.00138	CbGeAlD
Dasatinib—JAK2—lymph node—cervical cancer	0.000389	0.00137	CbGeAlD
Dasatinib—EPHA2—lymph node—cervical cancer	0.000384	0.00135	CbGeAlD
Dasatinib—FYN—lymph node—cervical cancer	0.000384	0.00135	CbGeAlD
Dasatinib—CYP1B1—uterus—cervical cancer	0.000381	0.00134	CbGeAlD
Dasatinib—MAP4K5—lymph node—cervical cancer	0.000375	0.00132	CbGeAlD
Dasatinib—MAP3K3—lymph node—cervical cancer	0.000375	0.00132	CbGeAlD
Dasatinib—ABL1—female gonad—cervical cancer	0.000368	0.00129	CbGeAlD
Dasatinib—ABL1—vagina—cervical cancer	0.000366	0.00129	CbGeAlD
Dasatinib—EPHB6—lymph node—cervical cancer	0.000358	0.00126	CbGeAlD
Dasatinib—YES1—lymph node—cervical cancer	0.000346	0.00122	CbGeAlD
Dasatinib—CYP1B1—female reproductive system—cervical cancer	0.000342	0.0012	CbGeAlD
Dasatinib—ABCG2—uterine cervix—cervical cancer	0.00034	0.0012	CbGeAlD
Dasatinib—PDGFRA—lymph node—cervical cancer	0.00034	0.0012	CbGeAlD
Dasatinib—SRC—lymph node—cervical cancer	0.000333	0.00117	CbGeAlD
Dasatinib—CYP1A1—epithelium—cervical cancer	0.000326	0.00115	CbGeAlD
Dasatinib—ABCG2—decidua—cervical cancer	0.000324	0.00114	CbGeAlD
Dasatinib—CYP1A1—uterine cervix—cervical cancer	0.000323	0.00114	CbGeAlD
Dasatinib—CYP3A5—uterine cervix—cervical cancer	0.000316	0.00111	CbGeAlD
Dasatinib—CYP1B1—female gonad—cervical cancer	0.000311	0.0011	CbGeAlD
Dasatinib—ABCG2—endometrium—cervical cancer	0.000308	0.00108	CbGeAlD
Dasatinib—MAP2K5—lymph node—cervical cancer	0.000306	0.00108	CbGeAlD
Dasatinib—CYP1A2—renal system—cervical cancer	0.000306	0.00108	CbGeAlD
Dasatinib—CYP1A1—renal system—cervical cancer	0.000302	0.00106	CbGeAlD
Dasatinib—CSF1R—lymph node—cervical cancer	0.000299	0.00105	CbGeAlD
Dasatinib—ABCG2—mammalian vulva—cervical cancer	0.000298	0.00105	CbGeAlD
Dasatinib—CYP3A5—renal system—cervical cancer	0.000295	0.00104	CbGeAlD
Dasatinib—ABCG2—uterus—cervical cancer	0.000284	0.000998	CbGeAlD
Dasatinib—CYP1A1—mammalian vulva—cervical cancer	0.000283	0.000994	CbGeAlD
Dasatinib—KIT—lymph node—cervical cancer	0.000272	0.000956	CbGeAlD
Dasatinib—CYP1A1—uterus—cervical cancer	0.000269	0.000947	CbGeAlD
Dasatinib—PDGFRB—lymph node—cervical cancer	0.000265	0.000933	CbGeAlD
Dasatinib—CYP1A1—female reproductive system—cervical cancer	0.000242	0.000851	CbGeAlD
Dasatinib—ABL1—lymph node—cervical cancer	0.000236	0.000832	CbGeAlD
Dasatinib—ABCG2—female gonad—cervical cancer	0.000232	0.000816	CbGeAlD
Dasatinib—ABCG2—vagina—cervical cancer	0.000231	0.000811	CbGeAlD
Dasatinib—CYP3A4—renal system—cervical cancer	0.000222	0.00078	CbGeAlD
Dasatinib—CYP1A1—female gonad—cervical cancer	0.00022	0.000775	CbGeAlD
Dasatinib—CYP1A1—vagina—cervical cancer	0.000219	0.00077	CbGeAlD
Dasatinib—CYP3A5—female gonad—cervical cancer	0.000215	0.000758	CbGeAlD
Dasatinib—CYP3A5—vagina—cervical cancer	0.000214	0.000753	CbGeAlD
Dasatinib—CYP1B1—lymph node—cervical cancer	0.0002	0.000705	CbGeAlD
Dasatinib—CYP3A4—female reproductive system—cervical cancer	0.000178	0.000625	CbGeAlD
Dasatinib—ABCB1—epithelium—cervical cancer	0.000169	0.000595	CbGeAlD
Dasatinib—ABCB1—uterine cervix—cervical cancer	0.000168	0.00059	CbGeAlD
Dasatinib—ABCB1—decidua—cervical cancer	0.00016	0.000562	CbGeAlD
Dasatinib—ABCB1—renal system—cervical cancer	0.000157	0.000552	CbGeAlD
Dasatinib—ABCB1—endometrium—cervical cancer	0.000152	0.000534	CbGeAlD
Dasatinib—ABCG2—lymph node—cervical cancer	0.000149	0.000525	CbGeAlD
Dasatinib—ABCB1—mammalian vulva—cervical cancer	0.000147	0.000516	CbGeAlD
Dasatinib—CYP1A1—lymph node—cervical cancer	0.000142	0.000498	CbGeAlD
Dasatinib—ABCB1—uterus—cervical cancer	0.00014	0.000492	CbGeAlD
Dasatinib—ABCB1—female reproductive system—cervical cancer	0.000126	0.000442	CbGeAlD
Dasatinib—ABCB1—female gonad—cervical cancer	0.000114	0.000402	CbGeAlD
Dasatinib—ABCB1—vagina—cervical cancer	0.000114	0.0004	CbGeAlD
Dasatinib—ABCB1—lymph node—cervical cancer	7.35e-05	0.000259	CbGeAlD
Dasatinib—PDGFRB—Signaling Pathways—HES1—cervical cancer	1.3e-05	4.2e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—EGFR—cervical cancer	1.3e-05	4.2e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—FGFR3—cervical cancer	1.3e-05	4.2e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—STAT3—cervical cancer	1.29e-05	4.18e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—EGFR—cervical cancer	1.29e-05	4.17e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—NOTCH1—cervical cancer	1.29e-05	4.17e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—NOTCH1—cervical cancer	1.28e-05	4.15e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CASP8—cervical cancer	1.28e-05	4.15e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—EGFR—cervical cancer	1.27e-05	4.12e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HES1—cervical cancer	1.27e-05	4.12e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NOTCH2—cervical cancer	1.27e-05	4.11e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—EGFR—cervical cancer	1.27e-05	4.11e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CASP8—cervical cancer	1.27e-05	4.1e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TERT—cervical cancer	1.26e-05	4.09e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—MTOR—cervical cancer	1.26e-05	4.08e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—CD4—cervical cancer	1.26e-05	4.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—EGFR—cervical cancer	1.26e-05	4.06e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HES1—cervical cancer	1.25e-05	4.05e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—TP53—cervical cancer	1.25e-05	4.05e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MTOR—cervical cancer	1.25e-05	4.04e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—TP53—cervical cancer	1.25e-05	4.03e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—TP53—cervical cancer	1.23e-05	3.99e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—MTOR—cervical cancer	1.23e-05	3.98e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—CTNNB1—cervical cancer	1.23e-05	3.98e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—CD4—cervical cancer	1.23e-05	3.98e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—FGFR3—cervical cancer	1.23e-05	3.96e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—STAT3—cervical cancer	1.21e-05	3.93e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—STAT3—cervical cancer	1.21e-05	3.93e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—EGFR—cervical cancer	1.21e-05	3.92e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HES1—cervical cancer	1.21e-05	3.9e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—FGFR3—cervical cancer	1.2e-05	3.87e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—EGFR—cervical cancer	1.19e-05	3.86e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HES1—cervical cancer	1.19e-05	3.85e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—TP53—cervical cancer	1.19e-05	3.84e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—CTNNB1—cervical cancer	1.18e-05	3.82e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—EGFR—cervical cancer	1.17e-05	3.8e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.17e-05	3.79e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—TP53—cervical cancer	1.17e-05	3.79e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—MTHFR—cervical cancer	1.17e-05	3.78e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—MTOR—cervical cancer	1.17e-05	3.77e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—CD4—cervical cancer	1.16e-05	3.76e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—FGFR3—cervical cancer	1.16e-05	3.75e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MTHFR—cervical cancer	1.16e-05	3.75e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—TERT—cervical cancer	1.16e-05	3.74e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—STAT3—cervical cancer	1.15e-05	3.73e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NOTCH1—cervical cancer	1.15e-05	3.72e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—FGFR3—cervical cancer	1.15e-05	3.71e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—CASP3—cervical cancer	1.15e-05	3.71e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MTOR—cervical cancer	1.14e-05	3.69e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TERT—cervical cancer	1.14e-05	3.68e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—MTOR—cervical cancer	1.14e-05	3.68e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—CD4—cervical cancer	1.13e-05	3.67e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CA9—cervical cancer	1.13e-05	3.65e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOTCH2—cervical cancer	1.13e-05	3.64e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—NOTCH1—cervical cancer	1.12e-05	3.64e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—CTNNB1—cervical cancer	1.12e-05	3.62e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TERT—cervical cancer	1.11e-05	3.61e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—MTOR—cervical cancer	1.11e-05	3.6e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—CD4—cervical cancer	1.11e-05	3.59e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CASP8—cervical cancer	1.11e-05	3.59e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—MTOR—cervical cancer	1.11e-05	3.58e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CD4—cervical cancer	1.11e-05	3.58e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—CTNNB1—cervical cancer	1.11e-05	3.58e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—EGFR—cervical cancer	1.1e-05	3.57e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—EGFR—cervical cancer	1.1e-05	3.57e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—EGFR—cervical cancer	1.1e-05	3.56e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MTOR—cervical cancer	1.1e-05	3.56e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TERT—cervical cancer	1.1e-05	3.55e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—MTOR—cervical cancer	1.1e-05	3.55e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—CD4—cervical cancer	1.09e-05	3.54e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—CTNNB1—cervical cancer	1.09e-05	3.53e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NOTCH1—cervical cancer	1.09e-05	3.52e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—MTHFR—cervical cancer	1.06e-05	3.43e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—FGFR3—cervical cancer	1.06e-05	3.43e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TERT—cervical cancer	1.06e-05	3.42e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—EGFR—cervical cancer	1.06e-05	3.42e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—MTOR—cervical cancer	1.06e-05	3.41e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CD4—cervical cancer	1.05e-05	3.41e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—MTOR—cervical cancer	1.05e-05	3.4e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CASP3—cervical cancer	1.05e-05	3.39e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—EGFR—cervical cancer	1.05e-05	3.39e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—CD4—cervical cancer	1.05e-05	3.39e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FGFR3—cervical cancer	1.04e-05	3.38e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TERT—cervical cancer	1.04e-05	3.38e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HES1—cervical cancer	1.04e-05	3.37e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—MTOR—cervical cancer	1.04e-05	3.37e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CD4—cervical cancer	1.04e-05	3.36e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—CTNNB1—cervical cancer	1.03e-05	3.34e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—STAT3—cervical cancer	1.03e-05	3.33e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—cervical cancer	1.03e-05	3.32e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FGFR3—cervical cancer	1.02e-05	3.31e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—cervical cancer	1.02e-05	3.29e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—MTOR—cervical cancer	1.01e-05	3.27e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CTNNB1—cervical cancer	1.01e-05	3.27e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CASP3—cervical cancer	1.01e-05	3.27e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—CD4—cervical cancer	1.01e-05	3.27e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—CTNNB1—cervical cancer	1.01e-05	3.26e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FGFR3—cervical cancer	1.01e-05	3.26e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NOTCH1—cervical cancer	9.95e-06	3.22e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—CTNNB1—cervical cancer	9.87e-06	3.19e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—cervical cancer	9.85e-06	3.19e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CTNNB1—cervical cancer	9.82e-06	3.18e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CASP8—cervical cancer	9.82e-06	3.18e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NOTCH1—cervical cancer	9.81e-06	3.17e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—STAT3—cervical cancer	9.75e-06	3.16e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CTNNB1—cervical cancer	9.75e-06	3.15e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—EGFR—cervical cancer	9.74e-06	3.15e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—CTNNB1—cervical cancer	9.72e-06	3.14e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FGFR3—cervical cancer	9.7e-06	3.14e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MTOR—cervical cancer	9.65e-06	3.12e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—STAT3—cervical cancer	9.64e-06	3.12e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—MTOR—cervical cancer	9.62e-06	3.11e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NOTCH1—cervical cancer	9.6e-06	3.11e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—CD4—cervical cancer	9.6e-06	3.11e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FGFR3—cervical cancer	9.57e-06	3.1e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—STAT3—cervical cancer	9.51e-06	3.08e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NOTCH1—cervical cancer	9.46e-06	3.06e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—EGFR—cervical cancer	9.36e-06	3.03e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CTNNB1—cervical cancer	9.35e-06	3.03e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—EGFR—cervical cancer	9.35e-06	3.03e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—CTNNB1—cervical cancer	9.31e-06	3.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CTNNB1—cervical cancer	9.24e-06	2.99e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HES1—cervical cancer	9.23e-06	2.99e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TERT—cervical cancer	9.14e-06	2.96e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—MTOR—cervical cancer	9.12e-06	2.95e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD4—cervical cancer	9.11e-06	2.95e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NOTCH1—cervical cancer	9.1e-06	2.95e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—cervical cancer	9.08e-06	2.94e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—STAT3—cervical cancer	9e-06	2.91e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NOTCH1—cervical cancer	8.99e-06	2.91e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—CTNNB1—cervical cancer	8.97e-06	2.9e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CASP3—cervical cancer	8.88e-06	2.87e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—EGFR—cervical cancer	8.86e-06	2.87e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—STAT3—cervical cancer	8.82e-06	2.85e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—STAT3—cervical cancer	8.79e-06	2.84e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—EGFR—cervical cancer	8.76e-06	2.83e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CA9—cervical cancer	8.71e-06	2.82e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—EGFR—cervical cancer	8.65e-06	2.8e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MTOR—cervical cancer	8.62e-06	2.79e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—STAT3—cervical cancer	8.6e-06	2.78e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—STAT3—cervical cancer	8.56e-06	2.77e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CTNNB1—cervical cancer	8.56e-06	2.77e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—CTNNB1—cervical cancer	8.53e-06	2.76e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—STAT3—cervical cancer	8.5e-06	2.75e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—STAT3—cervical cancer	8.47e-06	2.74e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—MTOR—cervical cancer	8.42e-06	2.73e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—CD4—cervical cancer	8.41e-06	2.72e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FGFR3—cervical cancer	8.38e-06	2.71e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—EGFR—cervical cancer	8.18e-06	2.65e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MTOR—cervical cancer	8.16e-06	2.64e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—STAT3—cervical cancer	8.15e-06	2.64e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—STAT3—cervical cancer	8.11e-06	2.62e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TERT—cervical cancer	8.09e-06	2.62e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CTNNB1—cervical cancer	8.09e-06	2.62e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—MTOR—cervical cancer	8.08e-06	2.61e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD4—cervical cancer	8.06e-06	2.61e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—STAT3—cervical cancer	8.05e-06	2.6e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—EGFR—cervical cancer	8.01e-06	2.59e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—EGFR—cervical cancer	8.01e-06	2.59e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—EGFR—cervical cancer	7.99e-06	2.58e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CASP3—cervical cancer	7.93e-06	2.57e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NOTCH1—cervical cancer	7.87e-06	2.55e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—STAT3—cervical cancer	7.82e-06	2.53e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—EGFR—cervical cancer	7.82e-06	2.53e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EGFR—cervical cancer	7.78e-06	2.52e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EGFR—cervical cancer	7.72e-06	2.5e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—EGFR—cervical cancer	7.7e-06	2.49e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CTNNB1—cervical cancer	7.64e-06	2.47e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—MTHFR—cervical cancer	7.61e-06	2.46e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CASP3—cervical cancer	7.5e-06	2.43e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—CTNNB1—cervical cancer	7.47e-06	2.42e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—STAT3—cervical cancer	7.46e-06	2.41e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MTOR—cervical cancer	7.46e-06	2.41e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CD4—cervical cancer	7.44e-06	2.41e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—STAT3—cervical cancer	7.43e-06	2.4e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGFR3—cervical cancer	7.42e-06	2.4e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EGFR—cervical cancer	7.41e-06	2.4e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EGFR—cervical cancer	7.37e-06	2.39e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—cervical cancer	7.35e-06	2.38e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MTOR—cervical cancer	7.35e-06	2.38e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EGFR—cervical cancer	7.32e-06	2.37e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CTNNB1—cervical cancer	7.23e-06	2.34e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MTOR—cervical cancer	7.2e-06	2.33e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—MTHFR—cervical cancer	7.19e-06	2.32e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CTNNB1—cervical cancer	7.16e-06	2.32e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—EGFR—cervical cancer	7.11e-06	2.3e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MTOR—cervical cancer	7.08e-06	2.29e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—STAT3—cervical cancer	7.05e-06	2.28e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOTCH1—cervical cancer	6.97e-06	2.25e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MTOR—cervical cancer	6.82e-06	2.21e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—cervical cancer	6.78e-06	2.19e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CASP3—cervical cancer	6.76e-06	2.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—cervical cancer	6.75e-06	2.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MTOR—cervical cancer	6.73e-06	2.18e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—cervical cancer	6.73e-06	2.18e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—STAT3—cervical cancer	6.66e-06	2.16e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CASP3—cervical cancer	6.62e-06	2.14e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CTNNB1—cervical cancer	6.61e-06	2.14e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CTNNB1—cervical cancer	6.52e-06	2.11e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CASP3—cervical cancer	6.52e-06	2.11e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—STAT3—cervical cancer	6.51e-06	2.11e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—cervical cancer	6.48e-06	2.1e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—cervical cancer	6.41e-06	2.07e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CTNNB1—cervical cancer	6.38e-06	2.06e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—STAT3—cervical cancer	6.31e-06	2.04e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CTNNB1—cervical cancer	6.28e-06	2.03e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CASP3—cervical cancer	6.27e-06	2.03e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—STAT3—cervical cancer	6.24e-06	2.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CASP3—cervical cancer	6.19e-06	2e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—cervical cancer	6.05e-06	1.96e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CTNNB1—cervical cancer	6.05e-06	1.96e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CTNNB1—cervical cancer	5.97e-06	1.93e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—cervical cancer	5.92e-06	1.91e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MTOR—cervical cancer	5.9e-06	1.91e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—cervical cancer	5.76e-06	1.86e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—cervical cancer	5.74e-06	1.86e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—cervical cancer	5.73e-06	1.85e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—cervical cancer	5.69e-06	1.84e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—cervical cancer	5.68e-06	1.84e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—cervical cancer	5.67e-06	1.84e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—cervical cancer	5.56e-06	1.8e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—cervical cancer	5.48e-06	1.77e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—cervical cancer	5.43e-06	1.76e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—cervical cancer	5.27e-06	1.71e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—cervical cancer	5.24e-06	1.69e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—cervical cancer	5.23e-06	1.69e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MTOR—cervical cancer	5.22e-06	1.69e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—cervical cancer	5.2e-06	1.68e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—cervical cancer	5.16e-06	1.67e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—cervical cancer	5.08e-06	1.64e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—cervical cancer	5.05e-06	1.64e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—cervical cancer	4.98e-06	1.61e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—cervical cancer	4.81e-06	1.56e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—cervical cancer	4.8e-06	1.55e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—cervical cancer	4.79e-06	1.55e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—cervical cancer	4.73e-06	1.53e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—cervical cancer	4.63e-06	1.5e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—cervical cancer	4.58e-06	1.48e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—cervical cancer	4.56e-06	1.47e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—cervical cancer	4.33e-06	1.4e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—cervical cancer	4.24e-06	1.37e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—cervical cancer	4.18e-06	1.35e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—cervical cancer	4.14e-06	1.34e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—cervical cancer	4.04e-06	1.31e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—cervical cancer	4.02e-06	1.3e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—cervical cancer	3.97e-06	1.29e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—cervical cancer	3.67e-06	1.19e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—cervical cancer	3.54e-06	1.14e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—cervical cancer	3.48e-06	1.13e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—cervical cancer	3.08e-06	9.96e-06	CbGpPWpGaD
